Meeting
2024 ASCO Genitourinary Cancers Symposium
Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate, in patients with prostate cancer including those previously treated with enzalutamide.
Authors
Jose W. Avitia
New Mexico Oncology Hematology Consultants Ltd., Albuquerque, NM
Jose W. Avitia , Neal D. Shore , Luke T. Nordquist , Ryan J. Malone , David Morris , Cody J. Peer , William Richardson , Keith Thomas Schmidt , William Douglas Figg , Jacqueline M. Walling , Katherine McDougall , Joel Robert Eisner , William R. Moore , Ronald F. Tutrone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04729114
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 140)
DOI
10.1200/JCO.2024.42.4_suppl.140
Abstract #
140
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).
First Author: Tim Warneke
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2023 ASCO Annual Meeting
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
First Author: Neal D. Shore
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate in patients (pts) with advanced prostate cancer.
First Author: Jose W. Avitia